University of California San Francisco
Give to UCSF
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s
New CAR-T gene therapy techniques could extend survival for patients with glioblastoma.
UCSF scientists have been awarded more than $30 million to develop “tissue GPS,” a new system using engineered T cells to guide therapies directly to their targets in the brain to treat neurological diseases like cancer, multiple sclerosis and Alzheimer’s.
Researchers recently identified a universal, essential biomarker for the childhood cancer neuroblastoma – and the biomarker could be a potential new target for treatment. Neuroblastoma accounts for
A new drug candidate permanently modifies a wily cancer-causing mutation, paving the way for making pancreatic cancer treatable, or perhaps even curable.
Juvenile myelomonocytic leukemia (JMML) is a rare but aggressive childhood leukemia. While hematopoietic stem cell transplantation is curative for some patients, approximately half of all patients see
Tracey Woodruff, PhD, MPH, offers insights on what her research on microplastics has led her to change how she and her family eats and what cleaning products she uses.
The new UCSF Health-John Muir Health Jean and Ken Hofmann Cancer Center at the Behring will bring a full spectrum of leading-edge cancer care close to home for people in the East Bay and surrounding areas.
Cancer immunotherapy is hindered by the fact that engineered immune cells often get worn out and depleted before they've killed a tumor. A UCSF team has identified mutations that give cancerous lymphoma T-cells their superpower and transfer those genes into engineered, therapeutic immune cells.
The two-year HEAL fellowship initiative operates in 10 countries but has a special focus on serving the Navajo Nation, which continues to suffer from the consequences of colonialism, including poor access to health care.
Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug.
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T
